This article is
- freely available
Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer
Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Hollings Cancer Center, Medical University of South Carolina, Charleston SC 29425 USA
* Author to whom correspondence should be addressed.
Received: 28 August 2010 / Accepted: 14 September 2010 / Published: 16 September 2010
Abstract: Aberrant crypt foci (ACF) are one of the earliest histopathological manifestations of colon cancer. In this review, we critically present the molecular, cellular, histopathological, and chemopreventive evidence that ACF are relevant biomarkers for colon cancer. The laboratory and clinical evidence are highly suggestive that ACF are in the pathway leading to colon cancer, but not all ACF will do so. The possible fate and outcome of ACF in the progression toward colon cancer may be dependent on a number of features that define their predictive power for the prevention or progression of cancer.
Keywords: aberrant crypt foci; biomarker; colon cancer; chemoprevention
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Wargovich, M.J.; Brown, V.R.; Morris, J. Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer. Cancers 2010, 2, 1705-1716.
Wargovich MJ, Brown VR, Morris J. Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer. Cancers. 2010; 2(3):1705-1716.
Wargovich, Michael J.; Brown, Vondina R.; Morris, Jay. 2010. "Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer." Cancers 2, no. 3: 1705-1716.